Neridronate: From Experimental Data to Clinical Use

Corrado, Addolorata; Colìa, Ripalta; Cantatore, Francesco Paolo

doi:10.1177/1179559x17732971

Cited by 5 publications

(6 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The contact angle value, θ measured on the unmodified implant surface (θ = 87.5 ± 2.28 • ) is twice higher than that measured on the alendronate-modified surface (θ = 41.9 ± 2.0 • ). Results for this commercially available titanium dental implant [58], as well as alendronate-modified titanium surfaces [30,32], are in agreement with literature data.…”

Section: The Wetting Properties Of Implant Samplessupporting

confidence: 89%

“…Since the implantation procedure destroys part of the bones and surrounding tissues and often evokes an inflammatory reaction, thus limiting the implant response, researchers are focused on improving the osseonintegration of implants by using pharmaceutical compounds, like bisphosphonates, as bioactive and osteoinductive coatings [ 1 , 2 , 4 , 25 , 26 , 27 , 28 , 29 ]. The bisphosphonates (BP) class of synthetic drugs is frequently used for the treatment of bone diseases; osteoporosis, bone cancer, osteopenia, and Paget’s disease [ 2 , 7 , 30 , 31 , 32 ]. The BP’s pharmacological effect is related to their strong affinity for binding to the bone mineral phase and biochemical effect on bone cell, dominantly osteoclasts.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A New Insight into Coating’s Formation Mechanism Between TiO2 and Alendronate on Titanium Dental Implant

et al. 2020

View full text Add to dashboard Cite

Organophosphorus compounds, like bisphosphonates, drugs for treatment and prevention of bone diseases, have been successfully applied in recent years as bioactive and osseoinductive coatings on dental implants. An integrated experimental-theoretical approach was utilized in this study to clarify the mechanism of bisphosphonate-based coating formation on dental implant surfaces. Experimental validation of the alendronate coating formation on the titanium dental implant surface was carried out by X-ray photoelectron spectroscopy and contact angle measurements. Detailed theoretical simulations of all probable molecular implant surface/alendronate interactions were performed employing quantum chemical calculations at the density functional theory level. The calculated Gibbs free energies of (TiO2)10–alendronate interaction indicate a more spontaneous exergonic process when alendronate molecules interact directly with the titanium surface via two strong bonds, Ti–N and Ti–O, through simultaneous participation common to both phosphonate and amine branches. Additionally, the stability of the alendronate-modified implant during 7 day-immersion in a simulated saliva solution has been investigated by using electrochemical impedance spectroscopy. The alendronate coating was stable during immersion in the artificial saliva solution and acted as an additional barrier on the implant with overall resistivity, R ~ 5.9 MΩ cm2.

show abstract

Section: The Wetting Properties Of Implant Samplessupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

A New Insight into Coating’s Formation Mechanism Between TiO2 and Alendronate on Titanium Dental Implant

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Bisphosphonic acid-terminated PEG can thus be strongly bound to the Fe 3 O 4 nanoparticle surface. Moreover, neridronate is biocompatible and has been approved for clinical use in the treatment of various bone illnesses 37 .…”

Section: Resultsmentioning

confidence: 99%

Synthesis and modification of uniform PEG-neridronate-modified magnetic nanoparticles determines prolonged blood circulation and biodistribution in a mouse preclinical model

Horák

Kučka

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Magnetite (Fe 3 O 4 ) nanoparticles with uniform sizes of 10, 20, and 31 nm were prepared by thermal decomposition of Fe(III) oleate or mandelate in a high-boiling point solvent (>320 °C). To render the particles with hydrophilic and antifouling properties, their surface was coated with a PEG-containing bisphosphonate anchoring group. The PEGylated particles were characterized by a range of physicochemical methods, including dynamic light scattering, transmission electron microscopy, thermogravimetric analysis, Fourier transform infrared spectroscopy, and magnetization measurements. As the particle size increased from 10 to 31 nm, the amount of PEG coating decreased from 28.5 to 9 wt.%. The PEG formed a dense brush-like shell on the particle surface, which prevented particles from aggregating in water and PBS (pH 7.4) and maximized the circulation time in vivo . Magnetic resonance relaxometry confirmed that the PEG-modified Fe 3 O 4 nanoparticles had high relaxivity, which increased with increasing particle size. In the in vivo experiments in a mouse model, the particles provided visible contrast enhancement in the magnetic resonance images. Almost 70% of administrated 20-nm magnetic nanoparticles still circulated in the blood stream after four hours; however, their retention in the tumor was rather low, which was likely due to the antifouling properties of PEG.

show abstract

“…Neridronate has a good safety profile, except for some cases of flu-like symptoms that resolved within a few days [ 27 ]. In an open-label 3-year study that assessed safety of neridronate in children and adolescents with osteogenesis imperfecta (OI), no fatal event was registered, and serious adverse events were considered not treatment-related; moreover, no cases of osteonecrosis of the jaw or atypical femur fracture were reported [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study

et al. 2022

View full text Add to dashboard Cite

Introduction Bone loss is a major issue in patients affected by Duchenne muscular dystrophy (DMD), a rare musculoskeletal disorder, particularly in those treated with glucocorticoids (GCs). We aimed to assess the effectiveness of neridronate in terms of bone mineral density (BMD) changes in this population. Methods We retrospectively reviewed the records of patients affected by DMD receiving GCs referred to our outpatient from 2015 to 2020. All patients were treated with an intramuscular (IM) injection of neridronate (25 mg every month). Bone density was measured at the lumbar spine (LS; L1–L4 tract) using dual-energy x-ray absorptiometry (DXA) (GE Lunar), no more than 4 weeks before (T0) and after 1 year from neridronate treatment (T1). Results Eight boys with DMD were included with a mean age at diagnosis of 4.75 ± 2.81 years. Six of them were non-ambulant and two of them had previous low-trauma fractures (a distal femur fracture and a vertebral compression fracture, respectively). All patients were receiving deflazacort [median duration of therapy 11.5 years (interquartile range 2–25)]. At the DXA evaluation (T0), the mean L1–L4 BMD value was 0.716 ± 0.164 g/cm 2 . Six patients (75%) showed an L1–L4 Z -score height-adjusted of less than − 2. The mean age of neridronate initiation was 18.87 ± 6.81 years. All patients were supplemented with calcium carbonate and vitamin D at baseline. After 12 months of treatment (T1), the mean L1–L4 BMD value was 0.685 ± 0.190 g/cm 2 . Seven patients (87.5%) showed an L1–L4 Z -score of less than − 2. Changes in LS BMD and Z -score were not significant between T0 and T1 in our cohort ( p = 0.674 and p = 0.208, respectively) as well as among non-ambulant patients with DMD without previous fragility fractures. Conclusions In this study, we reported for the first time that neridronate may slow bone loss in GC-treated patients with DMD at 1-year follow-up.

show abstract

Neridronate: From Experimental Data to Clinical Use

Cited by 5 publications

References 58 publications

A New Insight into Coating’s Formation Mechanism Between TiO2 and Alendronate on Titanium Dental Implant

A New Insight into Coating’s Formation Mechanism Between TiO2 and Alendronate on Titanium Dental Implant

Synthesis and modification of uniform PEG-neridronate-modified magnetic nanoparticles determines prolonged blood circulation and biodistribution in a mouse preclinical model

Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study

Contact Info

Product

Resources

About